Pharmacovigilance

Patient safety and drug surveillance and are the key focus of the Pharmacovigilance Working Group (PVWG). From early drug development until the marketing authorization and throughout the entire lifecycle of a product, pharmacovigilance is a key element for classical medicines as well as new therapeutic approaches such as gene and cell therapy.

Scope

In line with the IFAPP’s overall strategy and mission to promote Pharmaceutical Medicine, the PVWG aim to emphasize the role of pharmacovigilance within the medical sciences in detecting, analyzing and preventing potential risks associated with drug therapy.

Objectives

Enhancing the awareness of pharmacovigilance in healthcare professionals (HCPs) non-HCPs
Facilitating patient engagement in pharmacovigilance (considering that patient safety at the center of all pharmacovigilance activities)
Contributing to education & training in clinical safety and in post-authorization safety
Sharing knowledge about pharmacovigilance approaches for new therapies (e.g. long-term follow-up requirements for cell & gene therapies in different regions/countries)
Exploring new technologies in pharmacovigilance (e.g. automation, generative artificial intelligence (AI)), spreading knowledge and potential applications for them
Supporting the further evolution of pharmacovigilance legislation and/or its harmonization across regions
Interacting with pharmacovigilance groups at NMAs and collaborating with other global / international organizations dealing with pharmacovigilance topics
Fostering the exchange of know-how and best practices in daily business among the WG members
Being a forum for those IFAPP members who would like to actively engage in pharmacovigilance matters at global level